Key result
Exenatide increased myocardial blood flow from 0.73 to 0.85 ml/g·min (P=0.0056) without changing overall myocardial glucose uptake in male patients with type 2 diabetes.
Why the study?
Does exenatide alter myocardial glucose uptake and increase myocardial blood flow in insulin-naive men with type 2 diabetes without coronary artery disease?
Population
8 male, insulin-naive, type 2 diabetes mellitus patients without coronary artery disease.
Comparison
Exenatide administered during a… vs Placebo administered during a…
Design
RCT, Randomized crossover, Double-blinded
Authors
Loading...
Exenatide failed to increase myocardial glucose uptake; challenges proposed GLP-1 cardioprotective mechanism and leaves open alternative pathways.
RCT (n=8)
Double-blind
crossover
Does exenatide alter myocardial glucose uptake and increase myocardial blood flow in insulin-naive men with type 2 diabetes without coronary artery disease?
Absolute Event Rate: 0.85% vs 0.73%
p-value: p=0.0056
Exenatide increases myocardial blood flow in T2DM patients without CAD, providing mechanistic insight into the cardioprotective effects of GLP-1 receptor agonists.
Gejl et al. (2012) conducted an RCT in Type 2 diabetes mellitus (n=8). Exenatide vs. Placebo was evaluated on Myocardial blood flow (MBF) in ml/g·min (p=0.0056). Exenatide increased myocardial blood flow from 0.73 to 0.85 ml/g·min (P=0.0056) without changing overall myocardial glucose uptake in male patients with type 2 diabetes.